Acorda Therapeutics Inc (NASDAQ:ACOR) Given Consensus Rating of “Hold” by Brokerages

Share on StockTwits

Acorda Therapeutics Inc (NASDAQ:ACOR) has received a consensus recommendation of “Hold” from the twelve analysts that are covering the stock, MarketBeat reports. Four analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $10.21.

Several brokerages have recently commented on ACOR. HC Wainwright reissued a “hold” rating and set a $6.00 price target on shares of Acorda Therapeutics in a research note on Tuesday, November 5th. ValuEngine raised Acorda Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. lowered Acorda Therapeutics from a “neutral” rating to an “underweight” rating and set a $1.40 price target on the stock. in a research note on Thursday, October 24th.

Shares of NASDAQ:ACOR traded down $0.23 during trading on Wednesday, hitting $1.83. 1,953,501 shares of the stock were exchanged, compared to its average volume of 1,249,384. The company has a fifty day moving average price of $2.03 and a two-hundred day moving average price of $4.74. The company has a market cap of $87.90 million, a PE ratio of 1.01 and a beta of 1.15. The company has a current ratio of 3.42, a quick ratio of 3.12 and a debt-to-equity ratio of 1.33. Acorda Therapeutics has a 12-month low of $1.49 and a 12-month high of $19.32.

Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported ($0.46) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.51) by $0.05. The business had revenue of $47.72 million for the quarter, compared to analyst estimates of $43.23 million. Acorda Therapeutics had a negative return on equity of 12.96% and a negative net margin of 155.89%. The company’s quarterly revenue was down 66.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.17 EPS. Equities research analysts anticipate that Acorda Therapeutics will post -2.9 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of the stock. Advisory Services Network LLC raised its position in shares of Acorda Therapeutics by 9.6% during the 2nd quarter. Advisory Services Network LLC now owns 40,000 shares of the biopharmaceutical company’s stock worth $307,000 after purchasing an additional 3,500 shares during the last quarter. Aperio Group LLC raised its position in shares of Acorda Therapeutics by 39.0% during the 2nd quarter. Aperio Group LLC now owns 14,124 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 3,961 shares during the last quarter. KBC Group NV acquired a new position in shares of Acorda Therapeutics during the 2nd quarter worth approximately $31,000. Comerica Bank raised its position in shares of Acorda Therapeutics by 22.5% during the 3rd quarter. Comerica Bank now owns 44,988 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 8,268 shares during the last quarter. Finally, Gabelli Funds LLC acquired a new position in shares of Acorda Therapeutics during the 2nd quarter worth approximately $80,000.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.

Recommended Story: What is a front-end load?

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Analysts Anticipate Centene Corp  Will Announce Earnings of $0.73 Per Share
Zacks: Analysts Anticipate Centene Corp Will Announce Earnings of $0.73 Per Share
ValuEngine Downgrades Diplomat Pharmacy  to Buy
ValuEngine Downgrades Diplomat Pharmacy to Buy
Ingersoll-Rand  Raised to “Outperform” at Wells Fargo & Co
Ingersoll-Rand Raised to “Outperform” at Wells Fargo & Co
Mamamancini’s  Upgraded to “Hold” by ValuEngine
Mamamancini’s Upgraded to “Hold” by ValuEngine
Liberum Capital Increases Barratt Developments  Price Target to GBX 650
Liberum Capital Increases Barratt Developments Price Target to GBX 650
Clinigen Group  Given “Buy” Rating at Peel Hunt
Clinigen Group Given “Buy” Rating at Peel Hunt


© 2006-2019 Ticker Report